Dzuveo is indicated for the management of acute moderate to severe pain in adult patients.
SUFENTANIL CITRATE — HOSPIRA, approved 2026-06-25 (ANDA074534).
1,116 reports across the top reactions. These are spontaneously reported events from the FDA Adverse Event Reporting System — they reflect reporting volume, not incidence or frequency, and a report does not mean the drug caused the event.